[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Northumbria Healthcare NHS Foundation Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":122},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,76,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100628324","structured-review-to-optimise-management-and-prevent-harm-in-copd-100628324",false,"NCT07460154","Structured Review: To Optimise Management and Prevent Harm in COPD","A Structured Health Assessment in Frequent COPD Exacerbators: To Optimise Management, Identify Comorbidities and Prevent Oral Corticosteroid Related Harm","STOPMYCOPD","Inclusion Criteria\n\n1. COPD diagnosis documented in primary care records for at least 12 months.\n2. Age 35 years or older\n3. 3 or more prednisolone prescriptions in the past 12-months for ECOPD\\*\n4. Capacity to give informed consent\n5. Clinically stable at study entry (≥4 weeks following last ECOPD or other significant acute illness) \\* each prednisolone course separated by a minimum of 14 days from completion of the previous course.\n\nExclusion Criteria\n\n1. Maintenance OCS use currently or within the past 12 months \\*\n2. Anticipated inability to comply with the protocol\n3. Illness limiting life expectancy to less than 12 months (other than COPD)\n4. Housebound\n5. Lung transplant\n6. Domiciliary non-invasive ventilation \\*defined as ≥10mg daily for ≥ 6 weeks","ALL","35 Years",{"count":20,"type":21},96,"ESTIMATED","INTERVENTIONAL",[24],"NA","Background:\n\nChronic obstructive pulmonary disease (COPD) is a serious lung condition and the third leading cause of death worldwide. People with COPD have sudden and distressing flare-ups (exacerbations). These can be triggered by infections or occur without a clear cause. Flare-ups often lead to hospital admission, can cause a lasting health decline, increase the risk of dying and are strongly liked to lower income.\n\nSometimes, people are wrongly diagnosed with COPD, when they have a different health issue. Other diseases (like heart conditions) are common in people with COPD, and share similar symptoms. These have often not been diagnosed and worsening of these conditions can look like a flare-up of COPD, leading to incorrect treatment. Additionally, many people with COPD have not been offered appropriate treatments that would reduce their flare-up frequency.\n\nCOPD flare-ups are treated with steroid tablets (prednisolone), and sometimes antibiotics. Frequent use of prednisolone causes side effects such as weight gain, bone thinning (osteoporosis) and diabetes. Reducing how often people with COPD have flare-ups can reduce these side effects.\n\nThe investigators aim to reduce COPD flare-ups and prevent harm from prednisolone by improving the treatment of COPD, while also checking for other health conditions.\n\nThe goal:\n\nIn people with COPD, who take prednisolone for flare-ups (three of more times a year), the investigators want to see if a thorough assessment (that focuses on the treatment of COPD and diagnosis of other common health problems), reduces the number of flare-ups that need prednisolone over the next year.\n\nDesign:\n\nParticipants will attend a half-day hospital visit for a thorough check-up (a mini-MOT). The assessment includes a review by a doctor, questionnaires, blood tests, breathing tests, a scan of the chest (CT), and investigations on the heart. The investigators will make sure participants receive the correct treatment for their COPD.\n\nThe assessment will focus on three areas: lung health, identifying and treating important health issues outside of the lungs (that may be contributing or causing symptoms similar to COPD) and supporting changes in behaviours that can improve lung health. These factors (whether in the lungs, body or related to lifestyle) are known as treatable traits.\n\nThe investigators will also review participants prednisolone use and check for health problems that may have been caused by it. At the end of the assessment participants will be given a personalised treatment plan.\n\nParticipants will be followed up for 12 months, at 3 month intervals. During this time they will collect information on the number of emergency hospital visits, serious heart-related events, steroid tablets taken for COPD flare-ups and any deaths. They will ask participants to complete short questionnaires about their health and wellbeing.\n\nWho provided advise on this study :\n\nPreventing COPD flare-ups is a top priority, identified by The James Lind Alliance (a national research priority setting partnership). This study was reviewed by the Northumbria Lung Research Patient Advisory Group (people living with COPD). They felt the study was well-designed and likely to make a meaningful difference. People with experience in research and COPD also gave feedback, and changes were made, such as reducing travel requirements, based on their views. The research team has successfully completed studies that have led to real improvement in COPD care, and are committed to ensuring this study has a similar positive impact.\n\nSharing results:\n\nAt the end of the study results will be shared with the public, study participants, healthcare workers, commissioners and guideline advisory groups. The findings will be shared on online platforms, present them at national\u002Finternational conferences, and published in medical journals. The aim is to ensure findings improve clinical practice, policies and guidelines.",[27],"COPD",[27,29,30,31,32,33,34,35,36],"Structured assessment","Treatable Trait","Complex Intervention","Exaceration","Steroid","Oral Corticosteroid","Comorbidity","Multimorbity","RECRUITING","2026-04-20",{"date":40,"type":41},"2026-04-23","ACTUAL",{"date":43,"type":41},"2026-03-11",{"date":45,"type":21},"2029-03-02",{"name":47,"class":48},"Northumbria Healthcare NHS Foundation Trust","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":49},"100619654","large-language-model-for-understanding-and-monitoring-elderly-neurocognition-100619654","NCT07347431","Large Language Model for Understanding and Monitoring Elderly Neurocognition","LUMEN (Large Language Model for Understanding and Monitoring Elderly Neurocognition): A Clinical Feasibility Study With Nested Qualitative Evaluation for AI- Assisted Dementia Assessment","LUMEN","Carers of patients attending Memory Clinic appointments; Aged 18 or over; Both patients and cares can provide informed consent; Basic English literacy\n\nClinicians must have at least 2 years of specialist dementia care experience and be personally responsible for dementia diagnosis; Must be provide informed consent","65 Years",{"count":60,"type":21},60,"OBSERVATIONAL","Dementia affects millions of people worldwide, and early diagnosis is essential for getting the right care and support. Doctors rely on collateral histories (accounts from family members or caregivers) to understand changes in a person's memory and thinking. However, these histories can be incomplete, unstructured, or difficult to obtain, making diagnosis more challenging.\n\nThis study will test LUMEN (Large Language Model for Understanding and Monitoring Elderly Neurocognition), an AI-powered conversation tool designed to help caregivers describe their loved one's symptoms more effectively. By asking structured questions and guiding the conversation, LUMEN can create clear, well-organised reports for memory clinic doctors. This could make assessments quicker, more accurate, and less stressful for families.\n\nWe will test LUMEN in real-world clinics by asking caregivers and doctors to use it and provide feedback. We want to understand how easy it is to use, whether it could improve the quality of information shared, and how it fits into existing NHS memory clinic processes. We will also run co-production workshops with community groups to ensure the tool is accessible to people from diverse cultural and language backgrounds.\n\nThis research is exciting because it explores how artificial intelligence can improve dementia care. If successful, LUMEN could enhance the diagnostic process, reduce carer burden, and help more people access dementia support sooner. In the future, this tool could be used nationwide in memory clinics, improving care for thousands of families.",[64],"Dementia",[64,66,67,68],"Alzheimer's Disease","Artificial Intelligence","Large Language Models",{"date":70,"type":41},"2026-04-21",{"date":72,"type":41},"2026-03-19",{"date":74,"type":21},"2026-12-31",{"name":47,"class":48},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":49},"100530537","eosinopenia-in-severe-copd-exacerbation-100530537","NCT06188065","Eosinopenia in Severe COPD Exacerbation","Associates of, and Time to Recovery From, Eosinopenia in Severe COPD Exacerbation","A-TREC","Inclusion Criteria:\n\n* Admitted to hospital with primary clinical diagnosis of exacerbation of COPD\\*\n* Smoking history of at least 10 pack years\n* Airflow obstruction: FEV1\u002FFVC ratio \\\u003C 0.7 confirmed on historic or inpatient spirometry\n* Capacity to give informed consent to participate\n\nExclusion Criteria:\n\n* Parasitic infection, systemic fungal infection (excluding infection limited to nails or skin), eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome or other conditions associated with a high eosinophil count#\n* Active malignancy\n* Maintenance oral prednisolone or other systemic steroids, anti-interleukin 5 therapy or other medication known to influence eosinophils\n* Patients with poor venous access\n* Investigator confirmed history of asthma\n* Non-COPD related health problems which in the view of the primary investigator may compromise the conduct and completion of the study\n\nADDITIONAL CRITERIA FOR THE TIME TO RECOVERY FROM EOSINOPENIA ANALYSIS ONLY\n\nInclusion criteria:\n\n* Eosinopenia on admission\n* Uneventful recovery\\*\n\n  * Eosinopenia on admission who do not receive a further course of systemic corticosteroids or require emergency hospital admission for an acute illness in the six weeks following admission to hospital with a severe exacerbation of COPD.",{"count":85,"type":21},200,"The goals of this observational study are to identify factors independently associated with admission eosinopenia in patients with a severe exacerbation of chronic obstructive pulmonary disease (COPD) and to determine when blood eosinophil count (BEC) will recover to baseline stable state in patients who are admitted to hospital with a severe exacerbation of COPD and associated eosinopenia.\n\nThe main aims of the study are to:\n\n1. Identify demographic, physiological and clinical factors independently associated with admission eosinopenia in patients with a severe exacerbation of COPD\n2. Assess the time to recovery from eosinopenia to stable BEC following a severe exacerbation of COPD",[88],"Chronic Obstructive Pulmonary Disease","2026-04-13",{"date":91,"type":41},"2026-04-14",{"date":93,"type":41},"2024-01-22",{"date":95,"type":21},"2026-07",{"name":47,"class":48},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":104,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":49},"100502637","qist-collaborative---arthroplasty-research-cohort-arc-study-100502637","NCT05824845","QIST Collaborative - Arthroplasty Research Cohort (ARC) Study","QIST Collaborative - Arthroplasty Research Cohort (ARC) Study - a Collaborative, Longitudinal Observational Cohort Study of Patients Undergoing Primary Hip and Knee Replacements in the United Kingdom","Inclusion Criteria:\n\nParticipants must meet all of the inclusion criteria:\n\n1. UK Resident\n2. Able to read and understand documentation and questionnaires in English language\n3. Undergoing elective primary hip or knee arthroplasty (THR, TKR or UKR)\n4. Age 18 years or over\n5. Provides the necessary consents relating to data collection and use of study data, data linkage, future research and invitation to involvement in future trials\n\nExclusion Criteria:\n\nProvided a participant meets all of the inclusion criteria, there are no exclusion criteria for the cohort study.","18 Years",{"count":106,"type":21},5000,"The ARC Study is a national observational cohort study to investigate patient reported and clinical outcomes after hip and knee replacements. The study has the following objectives:\n\n1. To evaluate outcomes following hip and knee replacements.\n2. To determine risk factors for adverse outcomes in primary hip and knee replacements.\n3. To identify targets for future research and intervention in patients undergoing primary hip and knee replacements\n4. To provide a resource from which to identify potential participants for future clinical trials, and to use data collected in the ARC Study as comparison or control data for trial participants who have been randomised to receive one or more interventions.\n\nParticipants are recruited and consented online. Patients are invited to participate by collaborating surgical teams nationally in outpatient clinics at the time of being added to a waiting list, in addition to an advertising campaign to recruit patients. They are directed to an online portal where they will be able to review further information.\n\nConsent and data collection is completed electronically through patients entering data online. Baseline demographics and characteristics are recorded, including details of socio-demographics, lifestyle, health status and patient reported outcome measures (PROMs). Patients then undergo hip\u002Fknee replacement and postoperative rehabilitation according to the standard care and protocols of the hospital and the preferences of their treating surgeon.\n\nFollow-up data, including PROMs, is collected via online questionnaires up to two years following surgery. The study will ultimately also enable multiple trials to be embedded within the cohort study, using a 'Trials within Cohorts' (TwiCs) methodology.",[109,110],"Hip Arthritis","Knee Arthritis",[112,113],"Hip Replacement","Knee Replacement","2024-11-14",{"date":116,"type":41},"2024-11-18",{"date":118,"type":41},"2023-07-13",{"date":120,"type":21},"2031-05",{"name":47,"class":48},""]